RIGL : Summary for Rigel Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 1 hr 16 mins

Rigel Pharmaceuticals, Inc. (RIGL)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.51+0.09 (+3.72%)
At close: 4:00PM EST
People also watch
ARRYPGNXPTIESPPINBIX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.42
Open2.44
Bid2.01 x 100
Ask3.50 x 2000
Day's Range2.42 - 2.56
52 Week Range1.88 - 4.38
Volume419,160
Avg. Volume1,170,125
Market Cap248.33M
Beta1.18
PE Ratio (TTM)-3.48
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire44 minutes ago

    Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 214,000 shares of common stock to four new employees. Rigel granted stock options to purchase shares of Rigel's common stock to (i) three of the employees with an exercise price of $2.38 per share, the closing price of Rigel's common stock on December 30, 2016, the first trading date prior to January 3, 2017, the effective date of such grants and (ii) one employee with an exercise price of $2.51 per share, the closing price of Rigel's common stock on January 13, 2017, the first trading date prior to January 16, 2017 the effective date of such grant.

  • PR Newswire11 days ago

    Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy

    SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2017, at 2pm PST (see webcast details below). Rigel's presentation will review the fostamatinib clinical program, highlighting study data from the recently completed Phase 3 FIT clinical program in patients with immune thrombocytopenic purpura (ITP). Rigel will also present initial Phase 2 study results of fostamatinib in IgA nephropathy (IgAN), an autoimmune disease of the kidneys, and provide an update on its pipeline development.

  • Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio?
    Insider Monkeylast month

    Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]